Paediatric Liver, GI and Nutrition Centre, MowatLabs, King's College Hospital, London, UK.
Division of Gastroenterology and Hepatology, Department of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
J Pediatr Gastroenterol Nutr. 2018 Sep;67(3):377-382. doi: 10.1097/MPG.0000000000002007.
Wilson disease (WD) is a rare inborn error of copper metabolism with diverse manifestations. There has been no study of zinc (Zn), the copper's antagonist, in WD diagnosis and severity so far. Our aims were to evaluate serum Zn in WD and its correlation with the disease severity score (revised WD index). Although the ATP7B mutation analysis is highly accurate for WD diagnosis, it may not be readily available in a resource-limiting setting. We proposed a disease diagnostic score (Proposed WD diagnostic score) which incorporates serum Zn.
Medical records of WD and non-WD children seen at King's College Hospital from 2005 to 2015 were reviewed for the selected parameters using the Proposed WD diagnostic score. Available serum Zn data in WD children before disease diagnosis and the calculated severity score were statistically analyzed. Diagnostic values of the Proposed WD diagnostic score were evaluated.
Serum Zn level was significantly lower in 8 WD-acute liver failure (ALF) (5.8 [4.1-8.3] μmol/L) compared to 18 WD-non-ALF (13.5 [6.1-22.2] μmol/L) and 9 ALF from indeterminate cause (9.8 [7.0-12.1] μmol/L) (P < 0.001). Serum Zn significantly correlated with the revised WD index (r = -0.554, P = 0.004). The Proposed WD diagnostic score that included serum Zn level as 1 of the parameters had sensitivity and specificity of 87% and 99.2%, respectively.
Serum Zn is a novel parameter for diagnosis and correlates with severity of WD. The Proposed WD diagnostic score is useful while awaiting ATP7B mutation analysis.
威尔逊病(WD)是一种罕见的铜代谢先天性错误,具有多种表现。迄今为止,尚未有研究探讨 WD 诊断和严重程度中的锌(Zn),即铜的拮抗剂。我们的目的是评估 WD 患者的血清 Zn 及其与疾病严重程度评分(修订 WD 指数)的相关性。虽然 ATP7B 基因突变分析对 WD 诊断具有高度准确性,但在资源有限的情况下可能无法随时获得。我们提出了一种疾病诊断评分(拟议 WD 诊断评分),其中包含血清 Zn。
使用拟议 WD 诊断评分,回顾了 2005 年至 2015 年在 King's College 医院就诊的 WD 和非 WD 儿童的病历,以评估所选参数。对 WD 患儿在疾病诊断前的可用血清 Zn 数据和计算出的严重程度评分进行了统计学分析。评估了拟议 WD 诊断评分的诊断价值。
与 18 例 WD-非急性肝衰竭(ALF)(13.5[6.1-22.2]μmol/L)和 9 例原因不明的 ALF(9.8[7.0-12.1]μmol/L)相比,8 例 WD-ALF 患儿的血清 Zn 水平明显更低(5.8[4.1-8.3]μmol/L)(P<0.001)。血清 Zn 与修订后的 WD 指数显著相关(r=-0.554,P=0.004)。包含血清 Zn 水平作为 1 个参数的拟议 WD 诊断评分的敏感性和特异性分别为 87%和 99.2%。
血清 Zn 是诊断的新参数,与 WD 的严重程度相关。在等待 ATP7B 基因突变分析时,拟议 WD 诊断评分很有用。